Barriers to the treatment of hepatitis C

被引:152
作者
Morrill, JA
Shrestha, M
Grant, RW
机构
[1] Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA
[2] MGH Revere HealthCare Ctr, Revere, MA USA
关键词
hepatitis C virus infection; interferon and ribavirin therapy; barriers to treatment; substance abuse;
D O I
10.1111/j.1525-1497.2005.0161.x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Hepatitis C virus (HCV) infection is both prevalent and undertreated. OBJECTIVE: To identify barriers to HCV treatment in primary care practice. DESIGN:Cross-sectional study. SETTING AND PARTICIPANTS: A cohort of 208 HCV-infected patients under the care of a primary care physician (PCP) between December 2001 and April 2004 at a single academically affiliated community health center. MEASUREMENTS: Data were collected from the electronic medical record (EMR), the hospital clinical data repository, and interviews with PCPs. MAIN RESULTS: Our cohort consisted of 208 viremic patients with HCV infection. The mean age was 47.6 (+/- 9.7) years, 56% were male, and 79% were white. Fifty-seven patients (27.4% of the cohort) had undergone HCV treatment. Independent predictors of not being treated included: unmarried status (adjusted odds ratio [aOR] for treatment 0.36, P=.02), female gender (aOR 0.31, P=.01), current alcohol abuse (aOR 0.08, P=.0008), and a higher ratio of no-shows to total visits (aOR 0.005 per change of 1.0 in the ratio of no-shows to total visits, P=.002). The major PCP-identified reasons not to treat included: substance abuse (22.5%), patient preference (16%), psychiatric comorbidity (15%), and a delay in specialist input (12%). For 13% of the untreated patients, no reason was identified. CONCLUSION: HCV treatment was infrequent in our cohort of outpatients. Barriers to treatment included patient factors (patient preference, alcohol use, missed appointments), provider factors (reluctance to treat past substance abusers), and system factors (referral-associated delays). Multimodal interventions may be required to increase HCV treatment rates.
引用
收藏
页码:754 / 758
页数:5
相关论文
共 26 条
[1]   Treatment of chronic hepatitis C in a state correctional facility [J].
Allen, SA ;
Spaulding, AC ;
Osei, AM ;
Taylor, LE ;
Cabral, AM ;
Rich, JD .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (03) :187-190
[2]   The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[3]  
[Anonymous], 1997, NIH Consensus Statement
[4]  
[Anonymous], 2002, NIH CONSENS STATE SC, V19, P1
[5]   Treatment of hepatitis C infection in injection drug users [J].
Backmund, M ;
Meyer, K ;
Von Zielonka, M ;
Eichenlaub, D .
HEPATOLOGY, 2001, 34 (01) :188-193
[6]   Helping the urban poor stay with antiretroviral HIV drug therapy [J].
Bamberger, JD ;
Unick, J ;
Klein, P ;
Fraser, M ;
Chesney, M ;
Katz, MH .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2000, 90 (05) :699-701
[7]   Screening for hepatitis C virus infection in adults: Recommendation statement [J].
Berg, AO ;
Allan, JD ;
Orleans, CT ;
Siu, AL ;
Teutsch, SM ;
Westhoff, C ;
Woolf, SH .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (06) :462-464
[8]   Limited success of HCV antiviral therapy in United States veterans [J].
Cawthorne, CH ;
Rudat, KR ;
Burton, MS ;
Brown, KE ;
Luxon, BA ;
Janney, CG ;
Fimmel, CJ .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (01) :149-155
[9]   Screening for hepatitis C virus infection: A review of the evidence for the US Preventive Services Task Force [J].
Chou, R ;
Clark, EC ;
Helfand, M .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (06) :465-479
[10]   Treatment of chronic hepatitis C in active drug users [J].
Davis, GL ;
Rodrigue, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :215-217